Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Johann S.  De Bono

Employment - Institute of Cancer Research

Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex

Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex

Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex

Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex

Nobuaki  Matsubara

Honoraria - AstraZeneca; Bayer; Chugai Pharma (Inst); Janssen; MSD

Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Sanofi

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)

Nicolas  Penel

Research Funding - Bayer (Inst); Bayer (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag

Other Relationship - PharmaMar

Niven  Mehra

No Relationships to Disclose

Michael Paul  Kolinsky

Honoraria - Bayer; Janssen

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Merck

Research Funding - Janssen (Inst)

Emmanuelle  Bompas

No Relationships to Disclose

Susan  Feyerabend

Honoraria - Janssen

Consulting or Advisory Role - Astellas Pharma; Aventis Pharma; Bayer; Janssen

Travel, Accommodations, Expenses - Aventis Pharma

Gwenaelle  Gravis

Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi

Jae Young  Joung

No Relationships to Disclose

Kazuo  Nishimura

No Relationships to Disclose

Craig  Gedye

Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Novotech; Pfizer (Inst)

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)

Travel, Accommodations, Expenses - Merck Sharp & Dohme (Inst)

Joaquin  Mateo

Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Janssen; MSD; Roche (Inst)

Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Pfizer; Sanofi

Research Funding - AstraZeneca (Inst); Pfizer

Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Sanofi

Fred  Saad

Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi

Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Myovant Sciences; Pfizer; Sanofi

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst)

Karim  Fizazi

Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi

Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst)

Travel, Accommodations, Expenses - Janssen; MSD

Neal  Shore

No Relationships to Disclose

Jinyu  Kang

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Chintu  Desai

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Joseph E.  Burgents

Employment - Merck

Stock and Other Ownership Interests  - Merck

Elizabeth  Harrington

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Maha H. A.  Hussain

Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; Genentech; MLI PeerView; OncLive; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Research to Practice; Sanofi; UroToday; UroToday

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo Company; Genentech; Pfizer

Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)

Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753

Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer